- Home
- MDWD vs FSFG Comparison
MDWD vs FSFG Comparison
Compare MDWD & FSFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- FSFG
- Stock Information
- Founded
- MDWD 2000
- FSFG 2008
- Country
- MDWD Israel
- FSFG United States
- Employees
- MDWD N/A
- FSFG N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- FSFG Savings Institutions
- Sector
- MDWD Health Care
- FSFG Finance
- Exchange
- MDWD Nasdaq
- FSFG Nasdaq
- Market Cap
- MDWD 184.8M
- FSFG N/A
- IPO Year
- MDWD 2014
- FSFG 2008
- Fundamental
- Price
- MDWD $19.45
- FSFG $23.89
- Analyst Decision
- MDWD Strong Buy
- FSFG Buy
- Analyst Count
- MDWD 1
- FSFG 1
- Target Price
- MDWD $25.00
- FSFG $30.00
- AVG Volume (30 Days)
- MDWD 78.0K
- FSFG 11.5K
- Earning Date
- MDWD 03-20-2025
- FSFG 01-28-2025
- Dividend Yield
- MDWD N/A
- FSFG 2.51%
- EPS Growth
- MDWD N/A
- FSFG 201.94
- EPS
- MDWD N/A
- FSFG 2.74
- Revenue
- MDWD $19,720,000.00
- FSFG $73,624,000.00
- Revenue This Year
- MDWD $10.15
- FSFG N/A
- Revenue Next Year
- MDWD $25.62
- FSFG $2.77
- P/E Ratio
- MDWD N/A
- FSFG $8.73
- Revenue Growth
- MDWD N/A
- FSFG N/A
- 52 Week Low
- MDWD $11.04
- FSFG $14.55
- 52 Week High
- MDWD $24.00
- FSFG $30.94
- Technical
- Relative Strength Index (RSI)
- MDWD 55.03
- FSFG 39.99
- Support Level
- MDWD $19.59
- FSFG $23.01
- Resistance Level
- MDWD $20.62
- FSFG $26.12
- Average True Range (ATR)
- MDWD 0.83
- FSFG 0.81
- MACD
- MDWD 0.02
- FSFG -0.05
- Stochastic Oscillator
- MDWD 54.60
- FSFG 28.30
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.